Annual report pursuant to Section 13 and 15(d)

Subsequent Events (Details)

v2.4.0.6
Subsequent Events (Details) (USD $)
12 Months Ended 1 Months Ended 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Mar. 14, 2011
Dec. 31, 2012
Series D Preferred Stock [Member]
Dec. 31, 2011
Series D Preferred Stock [Member]
Mar. 31, 2013
Subsequent Event [Member]
Jan. 29, 2013
Subsequent Event [Member]
Dec. 31, 2012
Subsequent Event [Member]
Dec. 31, 2012
Subsequent Event [Member]
RXi Pharmaceuticals Corporation [Member]
Mar. 31, 2013
Subsequent Event [Member]
Series D Preferred Stock [Member]
Subsequent Events (Textual) [Abstract]                    
Series D Preferred Stockholders, total cash dividend paid         $ 4,704,000 $ 3,000,000        
Option to convert shares       10       1,129,032    
Series D Preferred Stock of Common Stock           11,290,320        
Outstanding shares of Series D Preferred Stock                   0
Issue of common stock shares                 50,000,000  
Milestone payments                 50,000,000  
Issue and outstanding of equity securities               100,000,000    
Common Stock, par value $ 0.01 $ 0.01       $ 0.01        
Number of trading days               10 days    
Closing share price/Weighted average price per share of Common Stock     $ 3.75         $ 4.87    
Common stock to Seller Parties at the closing               20,517,030    
Additional payment to seller parties in cash               190,000,000    
Revenue milestone achievement period               105 days    
Note purchase agreements, dated             January 25, 2013      
Purchasers for the sale of aggregate principal amount             $ 175,000,000      
Convertible Senior Notes             3.00%      
Issue of common stock / Issue of common stock against acquisition 305,560,763 305,560,763                
Common Stock, par value $ 0.01 $ 0.01       $ 0.01        
Number of trading days               10 days